Obesity and Upper Gastrointestinal Diseases.

Area of Science:

• Gastroenterology
• Oncology
• Metabolic Diseases

Background:

• Obesity is a significant risk factor for gastroesophageal reflux disease (GERD).
• GERD is associated with an increased incidence of Barrett's esophagus, esophageal adenocarcinoma, and gastric cardia cancer.
• Traditional studies often use body mass index (BMI) to define obesity, but emerging research highlights central obesity's role.

Purpose of the Study:

• To explore the multifaceted relationship between obesity and gastroesophageal reflux disease.
• To investigate the impact of central obesity on upper gastrointestinal disorders.
• To examine the efficacy of weight loss interventions for GERD symptoms and related functional gastrointestinal diseases.

Main Methods:

• Review of existing epidemiological and clinical studies correlating obesity metrics with GERD and upper gastrointestinal diseases.
• Analysis of the role of central obesity versus general obesity (BMI) in disease pathogenesis.
• Evaluation of evidence supporting weight loss as a therapeutic strategy.

Main Results:

• Central obesity is identified as a more critical factor than general obesity in GERD and associated upper gastrointestinal conditions.
• Weight loss interventions have demonstrated effectiveness in alleviating GERD symptoms.
• Obesity shows a significant correlation with functional gastrointestinal disorders, particularly upper abdominal pain, reflux, vomiting, and diarrhea.

Conclusions:

• Central obesity is a key driver of GERD and its complications, including esophageal and gastric cancers.
• Weight reduction is a viable strategy for managing GERD symptoms and improving functional gastrointestinal health.
• The impact of obesity on functional gastrointestinal diseases is more pronounced in the upper rather than lower gastrointestinal tract.